Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice
Open Access
- 20 November 2024
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (2) , 128-134
Abstract
Measurable residual disease (MRD) testing in patients with acute myelogenous leukemia (AML) represents a heterogenous assessment process designed to quantify leukemia-specific biomarkers that are not ascertainable by routine pathologic evaluation. The most common tools used to assess MRD are multiparameter flow cytometry (MPFC), and polymerase chain reaction (PCR) based tools, including quantitative or digital droplet PCR (qPCR, ddPCR), or next-generation sequencing (NGS) technologies. Collectively, MRD assessments have become an important clinical tool in the management of patients with AML. Despite progress, significant questions remain with respect to the appropriate timing, frequency, and methodology of MRD assessment, and whether or how to adapt therapy based on MRD results. Recent data from the Pre-MEASURE study, a retrospective cohort analysis of error corrected NGS based MRD assessment prior to allogeneic hematopoietic cell transplantation (alloHCT) in patients with AML, provides additional key information with respect to the emerging role of NGS-based technology in MRD assessment. In the context of this review, we evaluate the Pre-MEASURE study as well as other recent, high-quality assessments of MRD in AML. Our focus is to provide a practical assessment of the use of emerging MRD technologies in patients with AML with an emphasis on the role of peri-transplant MRD for the practicing clinician.Keywords
This publication has 70 references indexed in Scilit:
- Reverse transcriptase droplet digital PCR shows high resilience to PCR inhibitors from plant, soil and water samplesPlant Methods, 2014
- Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantationLeukemia, 2014
- Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapseHaematologica, 2014
- The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AMLBlood, 2013
- Minimal residual disease in acute myeloid leukaemiaNature Reviews Clinical Oncology, 2013
- Assessment of clinical analytical sensitivity and specificity of next-generation sequencing for detection of simple and complex mutationsBMC Genomic Data, 2013
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trialBlood, 2012
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesLeukemia, 2012
- Flow cytometric immunophenotyping for hematologic neoplasmsBlood, 2008
- Age and acute myeloid leukemiaBlood, 2006